TCL Archive Chemical Distribution To Grantees Delayed while HEW Considers Charging For It June 22, 1979
TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive Phase III Trial In Recurrent Disease Shows Lower Risk of Progression or Death by 34% June 28, 2013
TCL Archive Also in this 8-page issue: Cooperative groups tell Congress that NCI’s $115 million in support for adult cancer clinical trials is “chump change.” Trials would close faster, report results sooner, if funding were increased, regulatory issues streamlined. May 28, 2004
